Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203142 | 0.84 | MRGPRX4 (0.52) | FFAR1NPC1 | |
| SCHEMBL2745096 | 0.82 | PTPN1 (0.55) | FFAR1NPC1 | |
| SCHEMBL705457 | 0.81 | MGLL (0.58) | FFAR1SMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL24968812 | 0.79 | EGFR (0.54) | FFAR1NPC1ALDH1A1RAB9A | |
| SCHEMBL31503975 | 0.77 | LMNA (0.78) | NPC1ALDH1A1RAB9AMAPK1MAPT | |
| SCHEMBL371996 | 0.76 | ALDH1A1 (0.67) | FFAR1ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL29693563 | 0.76 | ALDH1A1 (0.67) | FFAR1ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL372306 | 0.76 | POLB (0.64) | FFAR1SMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL20620003 | 0.76 | MEN1 (0.71) | SMN1; SMN2NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL13615636 | 0.74 | MET (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | FFAR1 4745/4885SMN1; SMN2 4448/4885NPC1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.